Table 1 Results of GRADE assessment
Outcomes | Outcomes Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No of Participants (studies) | Quality of the evidence (GRADE) | Comments | |
|---|---|---|---|---|---|---|
Assumed risk | Corresponding risk | |||||
Placebo | Testosterone therapy alone | |||||
Total BMD (g/cm2) - average endpoint - short term Follow-up: less than 24 months | The mean total bmd (g/cm2) - average endpoint - short term in the intervention groups was 0.01 lower (0.02 lower to 0.01 higher) | 1081 (8 studies) | ⊕ ⊕ ⊝⊝ low1,2 | |||
Total BMD (g/cm2) - average endpoint - long term Follow-up: more than 24 months | The mean total bmd (g/cm2) - average endpoint - long term in the intervention groups was 0.04 higher (0.07 lower to 0.14 higher) | 156 (2 studies) | ⊕⊝⊝⊝ very low1,2,3,4 | |||
Fracture - short term Follow-up: 12 months | Study population | RR 0.92 (0.31 to 2.76) | 211 (1 study) | ⊕ ⊕ ⊝⊝ low4,5 | ||
59 per 1000 | 55 per 1000 (18 to 164) | |||||
Moderate | ||||||
59 per 1000 | 54 per 1000 (18 to 163) | |||||
Falls - short term Follow-up: 6 months | Study population | RR 0.70 (0.34 to 1.45) | 262 (1 study) | ⊕ ⊕ ⊝⊝ low4,5 | ||
121 per 1000 | 85 per 1000 (41 to 176) | |||||
Moderate | ||||||
121 per 1000 | 85 per 1000 (41 to 175) | |||||
Mortality - short term Follow-up: less than 24 months | Study population | RR 0.62 (0.3 to 1.31) | 598 (4 studies) | ⊕ ⊕ ⊝⊝ low3,5 | ||
50 per 1000 | 31 per 1000 (15 to 65) | |||||
Moderate | ||||||
13 per 1000 | 8 per 1000 (4 to 17) | |||||
Mortality - long term Follow-up: more than 24 months | Study population | RR 0.39 (0.1 to 1.42) | 131 (1 study) | ⊕⊝⊝⊝ very low3,4,5 | ||
113 per 1000 | 44 per 1000 (11 to 160) | |||||
Moderate | ||||||
113 per 1000 | 44 per 1000 (11 to 160) | |||||
Cardiovascular event - short term Follow-up: less than 24 months | Study population | RR 1.2 (0.44 to 3.26) | 1204 (8 studies) | ⊕⊝⊝⊝ very low1,3,5 | ||
50 per 1000 | 60 per 1000 (22 to 164) | |||||
Moderate | ||||||
39 per 1000 | 47 per 1000(17 to 127) | |||||
Cardiovascular event - long term Follow-up: more than 24 months | Study population | RR 1.42 (0.66 to 3.05) | 170 (2 studies) | ⊕ ⊕ ⊝⊝ low4,5 | ||
116 per 1000 | 165 per 1000 (77 to 355) | |||||
Moderate | ||||||
124 per 1000 | 176 per 1000(82 to 378) | |||||
Quality of life - average endpoint (AMS, high = worse) - short term Follow-up: less than 24 months | The mean quality of life - average endpoint (ams, high = worse) - short term in the intervention groups was 1.32 lower (2.11 to 0.52 lower) | 1328 (8 studies) | ⊕ ⊕ ⊕⊝ moderate6 | |||
Sexual function - average endpoint (IIEF score, high = well) - short term Follow-up: less than 24 years | The mean sexual function - average endpoint (iief score, high = well) - short term in the intervention groups was 1.48 higher (0.05 to 2.91 higher) | 503 (4 studies) | ⊕ ⊕ ⊝⊝ low1,3,7 | |||